Headlines about Biopharmx Corp (NYSE:BPMX) have been trending somewhat positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biopharmx Corp earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.8485669580683 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news stories that may have effected Accern’s rankings:
- BioPharmX Corporation (BPMX) noted a price change of 0.17% and ARCA biopharma, Inc. (ABIO) closes with a move … - Stocks Gallery (stocksgallery.com)
- Brokerages Set $3.38 Price Target for Biopharmx Corp (NYSE:BPMX) (americanbankingnews.com)
- Biopharmx Corp (BPMX) Mesa Adaptive MA Sitting Below FAMA - Evergreen Caller (evergreencaller.com)
- From A Very Different Angle: BioPharmX Corporation (BPMX), Synaptics Incorporated (SYNA) - AllStockNews (allstocknews.com)
- 2 Hot Stocks To Watch: BioPharmX (BPMX), Inphi (IPHI) - StockNewsMagazine (stocknewsmagazine.com)
Biopharmx Corp (NYSE:BPMX) opened at 0.2685 on Wednesday. The stock’s 50 day moving average is $0.43 and its 200-day moving average is $0.51. The stock’s market capitalization is $19.90 million. Biopharmx Corp has a 52 week low of $0.19 and a 52 week high of $1.22.
Separately, ValuEngine raised shares of Biopharmx Corp from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 24th.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.
